NASDAQ:OBSV - Obseva News Headlines

$9.08
+0.08 (+0.89 %)
(As of 08/20/2019 04:00 PM ET)
Today's Range
$9.00
Now: $9.08
$9.41
50-Day Range
$8.62
MA: $9.81
$11.3350
52-Week Range
$8.22
Now: $9.08
$19.40
Volume10,604 shs
Average Volume61,420 shs
Market Capitalization$412.96 million
P/E RatioN/A
Dividend YieldN/A
Beta0.91

Headlines

Obseva (NASDAQ OBSV) News Headlines

Source:
DateHeadline
ObsEva SA (OBSV) Q2 2019 Earnings Call TranscriptObsEva SA (OBSV) Q2 2019 Earnings Call Transcript
finance.yahoo.com - August 15 at 10:47 PM
Obseva SA (NASDAQ:OBSV) Receives Consensus Rating of "Buy" from BrokeragesObseva SA (NASDAQ:OBSV) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 15 at 3:35 AM
Edited Transcript of OBSV.O earnings conference call or presentation 7-Aug-19 12:00pm GMTEdited Transcript of OBSV.O earnings conference call or presentation 7-Aug-19 12:00pm GMT
finance.yahoo.com - August 13 at 6:17 PM
Obseva SA (NASDAQ:OBSV) Short Interest UpdateObseva SA (NASDAQ:OBSV) Short Interest Update
www.americanbankingnews.com - August 13 at 12:27 AM
Obsevas (OBSV) Buy Rating Reaffirmed at Royal Bank of CanadaObseva's (OBSV) Buy Rating Reaffirmed at Royal Bank of Canada
www.americanbankingnews.com - August 11 at 12:53 PM
ObsEva SA: ObsEva Reports Second Quarter 2019 Financial ResultsObsEva SA: ObsEva Reports Second Quarter 2019 Financial Results
www.finanznachrichten.de - August 7 at 10:41 AM
ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLCObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC
www.nasdaq.com - August 7 at 10:41 AM
ObsEva down 4% on stock sales deal with JefferiesObsEva down 4% on stock sales deal with Jefferies
seekingalpha.com - August 7 at 10:41 AM
ObsEva SA to Hold Second Quarter 2019 Financial...ObsEva SA to Hold Second Quarter 2019 Financial...
www.benzinga.com - August 5 at 9:38 AM
ObsEva SA to Hold Second Quarter 2019 Financial Results and Business Update Call on August 7, 2019ObsEva SA to Hold Second Quarter 2019 Financial Results and Business Update Call on August 7, 2019
finance.yahoo.com - August 5 at 9:38 AM
Obseva (OBSV) Set to Announce Earnings on MondayObseva (OBSV) Set to Announce Earnings on Monday
www.americanbankingnews.com - August 3 at 9:23 AM
Critical Survey: Obseva (NASDAQ:OBSV) versus Eyenovia (NASDAQ:EYEN)Critical Survey: Obseva (NASDAQ:OBSV) versus Eyenovia (NASDAQ:EYEN)
www.americanbankingnews.com - August 1 at 2:55 AM
ObsEva: Building A Top Tier Company Focused On Womens Health IssuesObsEva: Building A Top Tier Company Focused On Women's Health Issues
seekingalpha.com - July 31 at 10:12 AM
Obseva (NASDAQ:OBSV) Stock Rating Reaffirmed by Credit Suisse GroupObseva (NASDAQ:OBSV) Stock Rating Reaffirmed by Credit Suisse Group
www.americanbankingnews.com - July 29 at 1:15 PM
Short Interest in Obseva SA (NASDAQ:OBSV) Grows By 17.8%Short Interest in Obseva SA (NASDAQ:OBSV) Grows By 17.8%
www.americanbankingnews.com - July 27 at 5:18 PM
ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022
finance.yahoo.com - July 26 at 8:19 AM
ObsEva to Increase Issued Share Capital by Creating Additional Treasury SharesObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
finance.yahoo.com - July 18 at 10:31 AM
ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of NolasibanObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban
finance.yahoo.com - July 17 at 5:07 PM
ObsEva completes enrollment in late-stage study of linzagolix for heavy menstrual bleedingObsEva completes enrollment in late-stage study of linzagolix for heavy menstrual bleeding
seekingalpha.com - July 8 at 9:40 AM
New medical chief at ObsEvaNew medical chief at ObsEva
seekingalpha.com - July 1 at 9:45 AM
Here is What Hedge Funds Think About ObsEva SA (OBSV)Here is What Hedge Funds Think About ObsEva SA (OBSV)
finance.yahoo.com - June 29 at 9:36 AM
ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in ViennaObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna
finance.yahoo.com - June 21 at 12:14 PM
ObsEva advances Phase 3 trial for nolasiban following FDA meetingObsEva advances Phase 3 trial for nolasiban following FDA meeting
seekingalpha.com - June 19 at 11:41 AM
ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA MeetingObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting
finance.yahoo.com - June 19 at 11:41 AM
ObsEva completes patient enrollment in late-stage nolasiban trialObsEva completes patient enrollment in late-stage nolasiban trial
seekingalpha.com - June 4 at 9:51 AM
ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF OutcomesObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes
finance.yahoo.com - June 4 at 9:51 AM
Does The ObsEva SA (NASDAQ:OBSV) Share Price Fall With The Market?Does The ObsEva SA (NASDAQ:OBSV) Share Price Fall With The Market?
finance.yahoo.com - May 31 at 5:47 PM
Edited Transcript of OBSV.O earnings conference call or presentation 9-May-19 12:00pm GMTEdited Transcript of OBSV.O earnings conference call or presentation 9-May-19 12:00pm GMT
finance.yahoo.com - May 10 at 5:41 PM
Here’s What Hedge Funds Think About ObsEva SA (OBSV)Here’s What Hedge Funds Think About ObsEva SA (OBSV)
finance.yahoo.com - May 9 at 6:08 PM
ObsEva SA: ObsEva Reports First Quarter 2019 Financial ResultsObsEva SA: ObsEva Reports First Quarter 2019 Financial Results
www.finanznachrichten.de - May 9 at 9:46 AM
ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and EuropeObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe
finance.yahoo.com - May 9 at 9:46 AM
ObsEva Reports First Quarter 2019 Financial ResultsObsEva Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 9 at 9:46 AM
ObsEva SA (OBSV) Reports Q1 Loss, Lags Revenue EstimatesObsEva SA (OBSV) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 9 at 9:46 AM
ObsEva SA Announces that ObsEva’s Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019ObsEva SA Announces that ObsEva’s Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019
finance.yahoo.com - May 8 at 6:14 PM
The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With AmgenThe Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen
www.msn.com - May 3 at 9:52 AM
ObsEvas linzagolix shows long-term effect in extension studyObsEva's linzagolix shows long-term effect in extension study
seekingalpha.com - May 3 at 9:52 AM
ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated PainObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain
finance.yahoo.com - May 3 at 9:52 AM
ObsEva SA to Hold First Quarter 2019 Financial...ObsEva SA to Hold First Quarter 2019 Financial...
www.benzinga.com - May 1 at 9:34 AM
ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019
finance.yahoo.com - May 1 at 9:34 AM
ObsEva SA reports follow-up data from IMPLANT2 trialObsEva SA reports follow-up data from IMPLANT2 trial
seekingalpha.com - April 29 at 9:37 AM
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVFObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF
finance.yahoo.com - April 29 at 9:37 AM
ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019
finance.yahoo.com - March 24 at 6:20 PM
ObsEva SAObsEva SA
www.bloomberg.com - March 19 at 10:04 AM
ObsEva SA Estimate MomentumObsEva SA Estimate Momentum
www.nasdaq.com - March 18 at 6:15 PM
Edited Transcript of OBSV.O earnings conference call or presentation 5-Mar-19 1:00pm GMTEdited Transcript of OBSV.O earnings conference call or presentation 5-Mar-19 1:00pm GMT
finance.yahoo.com - March 6 at 10:02 AM
ObsEva SA (OBSV) Q4 2018 Earnings Conference Call TranscriptObsEva SA (OBSV) Q4 2018 Earnings Conference Call Transcript
finance.yahoo.com - March 5 at 5:37 PM
ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business UpdateObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update
finance.yahoo.com - March 5 at 10:17 AM
ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019
finance.yahoo.com - February 27 at 9:56 AM
Are ObsEva SA’s (NASDAQ:OBSV) Interest Costs Too High?Are ObsEva SA’s (NASDAQ:OBSV) Interest Costs Too High?
finance.yahoo.com - February 25 at 5:54 PM
Update: ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG TrialUpdate: ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial
globenewswire.com - January 24 at 10:03 AM
This page was last updated on 8/20/2019 by MarketBeat.com Staff

Featured Article: What is the Rule of 72?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel